Allostery Investments LP Takes Position in Evolus, Inc. (NASDAQ:EOLS)

Allostery Investments LP bought a new stake in Evolus, Inc. (NASDAQ:EOLS) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 431,117 shares of the company’s stock, valued at approximately $4,760,000. Evolus makes up 4.9% of Allostery Investments LP’s holdings, making the stock its 3rd biggest position. Allostery Investments LP owned about 0.68% of Evolus as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in EOLS. KBC Group NV bought a new position in shares of Evolus in the 4th quarter valued at about $49,000. IFP Advisors Inc grew its holdings in Evolus by 17,440.7% during the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock worth $52,000 after purchasing an additional 4,709 shares during the period. KLP Kapitalforvaltning AS acquired a new position in Evolus during the fourth quarter worth approximately $106,000. Quantbot Technologies LP bought a new stake in Evolus in the fourth quarter valued at approximately $118,000. Finally, Freestone Grove Partners LP acquired a new stake in shares of Evolus in the fourth quarter valued at approximately $140,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Evolus Price Performance

NASDAQ:EOLS opened at $11.80 on Friday. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The firm has a market cap of $750.33 million, a price-to-earnings ratio of -12.97 and a beta of 0.97. Evolus, Inc. has a 52 week low of $8.67 and a 52 week high of $17.82. The firm’s 50-day simple moving average is $12.02 and its 200 day simple moving average is $12.80.

Insider Activity

In other Evolus news, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $60,147.36. Following the transaction, the chief marketing officer now directly owns 95,671 shares of the company’s stock, valued at $1,268,597.46. This trade represents a 4.53 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Rui Avelar sold 27,904 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $370,007.04. Following the sale, the insider now directly owns 362,467 shares of the company’s stock, valued at approximately $4,806,312.42. This trade represents a 7.15 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 60,575 shares of company stock worth $794,369. Corporate insiders own 6.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on EOLS shares. BTIG Research began coverage on Evolus in a report on Thursday, April 17th. They set a “buy” rating and a $21.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price objective on shares of Evolus in a research report on Wednesday, April 9th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 target price on shares of Evolus in a report on Thursday, April 10th. Finally, Barclays increased their price target on shares of Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $23.75.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.